Table 1 Summary of patient characteristics
From: Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival
Group A | Group B | P | |
|---|---|---|---|
(n = 27) | (n = 26) | ||
Sex | |||
Male | 16 (59%) | 14 (53%) | |
Female | 11 (41%) | 12 (47%) | 0.74 |
Onset age | |||
< 45 | 16 (59%) | 12 (46%) | |
> 45 | 11 (41%) | 14 (54%) | 0.26 |
Pre-surgery KPS | |||
60–80 | 5 (18%) | 6 (23%) | |
> 80 | 22 (82%) | 20 (77%) | 0.42 |
Brain lobes involved in tumor | |||
1 | 14 (52%) | 15 (57%) | |
> 1 | 13 (48%) | 11 (43%) | 0.42 |
MGMT methylation | |||
Yes | 12 (44%) | 14 (54%) | |
No | 13 (48%) | 10 (38%) | |
Unknown | 2 (8%) | 2 (8%) | 0.78 |
IDH mutation | |||
Mutated | 5 (18.5%) | 8 (31%) | |
Wild type | 17 (63%) | 12 (46%) | |
Unknown | 5 (18.5%) | 6 (23%) | 0.14 |
TMZ therapeutic cycles | |||
6 | 27 (100%) | 0 | |
7–9 | 10 (38%) | ||
10–12 | 9 (34%) | ||
> 12 | 7 (28%) | < 0.001 | |
Total patient number | 27 | 26 | 53 |